MedPath

Woolcock Institute of Medical Research

Woolcock Institute of Medical Research logo
🇦🇺Australia
Ownership
Private
Established
1981-01-01
Employees
101
Market Cap
-
Website
http://www.woolcock.org.au

Clinical Trials

83

Active:4
Completed:36

Trial Phases

6 Phases

Early Phase 1:2
Phase 1:4
Phase 2:3
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (72 trials with phase data)• Click on a phase to view related trials

Not Applicable
51 (70.8%)
Phase 3
7 (9.7%)
Phase 4
5 (6.9%)
Phase 1
4 (5.6%)
Phase 2
3 (4.2%)
Early Phase 1
2 (2.8%)

A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults with Insomnia.

Phase 2
Recruiting
Conditions
Insomnia
Interventions
First Posted Date
2025-03-25
Last Posted Date
2025-04-01
Lead Sponsor
Woolcock Institute of Medical Research
Target Recruit Count
20
Registration Number
NCT06823752
Locations
🇦🇺

Woolcock Institute of Medical Research, Macquarie Park, New South Wales, Australia

A Novel Inhaled Formulation of Melatonin to Treat Adults with Insomnia: Pharmacokinetic Study

Early Phase 1
Not yet recruiting
Conditions
Insomnia
Interventions
Drug: Inhaled Melatonin (100 μg)
Drug: Oral Melatonin (4 mg)
First Posted Date
2025-03-25
Last Posted Date
2025-03-28
Lead Sponsor
Woolcock Institute of Medical Research
Target Recruit Count
5
Registration Number
NCT06801379
Locations
🇦🇺

Woolcock Institute of Medical Research, Macquarie Park, New South Wales, Australia

A Novel Inhaled Formulation of Melatonin to Treat Adults with Insomnia: Efficacy Study

Early Phase 1
Not yet recruiting
Conditions
Insomnia
Interventions
Drug: Inhaled Melatonin (100 μg)
Drug: Oral Melatonin (4 mg)
First Posted Date
2025-03-25
Last Posted Date
2025-03-28
Lead Sponsor
Woolcock Institute of Medical Research
Target Recruit Count
10
Registration Number
NCT06802913
Locations
🇦🇺

Woolcock Institute of Medical Research, Macquarie Park, New South Wales, Australia

The Feasibility of Overnight Time Restricted Eating and Impact on Glucose Levels in Shift Workers

Not Applicable
Active, not recruiting
Conditions
Shift Work
Eating Behaviors
First Posted Date
2024-11-13
Last Posted Date
2025-06-29
Lead Sponsor
Woolcock Institute of Medical Research
Target Recruit Count
30
Registration Number
NCT06686667
Locations
🇦🇺

The Sutherland Hospital, Caringbah, New South Wales, Australia

The Effects of Insomnia Treatment on Overnight Regulation of Emotional Memories and Risk for Mental Disorders

Not Applicable
Recruiting
Conditions
Depression, Anxiety
Insomnia Chronic
First Posted Date
2024-08-22
Last Posted Date
2025-03-26
Lead Sponsor
Woolcock Institute of Medical Research
Target Recruit Count
110
Registration Number
NCT06567210
Locations
🇦🇺

Woolcock Institute of Medical Research, Macquarie Park, New South Wales, Australia

  • Prev
  • 1
  • 2
  • 3
  • Next

News

Levofloxacin Shows Promise in Preventing Multidrug-Resistant Tuberculosis

A clinical trial in Vietnam demonstrated that a six-month course of daily levofloxacin significantly reduced the risk of developing multidrug-resistant tuberculosis (MDR-TB).

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.